What is HC Wainwright's Estimate for Invivyd Q1 Earnings?

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Invivyd in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.08 EPS and FY2028 earnings at $0.18 EPS.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $34.45 million.

Separately, D. Boral Capital reissued a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Friday, May 16th.

Invivyd Trading Down 2.8%

Invivyd stock traded down $0.03 during mid-day trading on Thursday, hitting $0.91. The company had a trading volume of 1,012,433 shares, compared to its average volume of 4,500,532. The stock's 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.74. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74. The company has a market capitalization of $109.04 million, a PE ratio of -0.46 and a beta of 0.40.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of Invivyd by 644.1% in the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after acquiring an additional 222,375 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Invivyd in the 4th quarter valued at $74,000. Barclays PLC increased its holdings in shares of Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after acquiring an additional 9,207 shares during the period. Jane Street Group LLC increased its holdings in shares of Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after acquiring an additional 87,358 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after acquiring an additional 227,463 shares during the period. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.